Gene expression for biodosimetry and effect prediction purposes: promises, pitfalls and future directions–key session ConRad 2021
P Ostheim, SA Amundson, C Badie… - … journal of radiation …, 2022 - Taylor & Francis
Purpose In a nuclear or radiological event, an early diagnostic or prognostic tool is needed
to distinguish unexposed from low-and highly exposed individuals with the latter requiring …
to distinguish unexposed from low-and highly exposed individuals with the latter requiring …
Randomized phase II trial of MIBG versus MIBG, vincristine, and irinotecan versus MIBG and vorinostat for patients with relapsed or refractory neuroblastoma: a report …
SG DuBois, MM Granger, S Groshen… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE 131I-metaiodobenzylguanidine (MIBG) is an active radiotherapeutic for
neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens …
neuroblastoma. The primary aim of this trial was to identify which of three MIBG regimens …
The DNA damage response to radiological imaging: from ROS and γH2AX foci induction to gene expression responses in vivo
M López-Riego, M Płódowska, M Lis-Zajęcka… - Radiation and …, 2023 - Springer
Candidate ionising radiation exposure biomarkers must be validated in humans exposed in
vivo. Blood from patients undergoing positron emission tomography–computed tomography …
vivo. Blood from patients undergoing positron emission tomography–computed tomography …
Peripheral blood transcript signatures after internal 131I-mIBG therapy in relapsed and refractory neuroblastoma patients identifies early and late biomarkers of …
AC Evans, T Setzkorn, DA Edmondson… - Radiation …, 2022 - meridian.allenpress.com
131I-metaiodobenzylguanidine (131I-mIBG) is a targeted radiation therapy developed for
the treatment of advanced neuroblastoma. We have previously shown that this patient cohort …
the treatment of advanced neuroblastoma. We have previously shown that this patient cohort …
Modulation of Radiation Biomarkers in a Randomized Phase II Study of 131I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma
K Campbell, S Groshen, AC Evans, S Wilson… - International Journal of …, 2023 - Elsevier
Purpose 131 I-metaiodobenzylguanidine (131 I-MIBG) has demonstrated efficacy as a
single agent in neuroblastoma. Recent trials have focused on 131 I-MIBG combination …
single agent in neuroblastoma. Recent trials have focused on 131 I-MIBG combination …
[PDF][PDF] Characterizing the relative biologic effectiveness following clinical and space-relevant ionizing radiation exposures and exploring curcumin nanoparticles as …
AC Evans - 2022 - osti.gov
Biodosimetry assays are employed as surrogate measurements or supplements to physical
ionizing radiation (IR) dosimetry that are based on assaying the outcomes of cellular DNA …
ionizing radiation (IR) dosimetry that are based on assaying the outcomes of cellular DNA …